Advertisement

Relation of Mortality to Failure to Prescribe Beta Blockers Acutely in Patients With Sustained Ventricular Tachycardia and Ventricular Fibrillation Following Acute Myocardial Infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry)

Published:September 15, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.07.033
      Sustained ventricular arrhythmias and heart failure are well-recognized complications after acute myocardial infarction (AMI) and have been associated with worse outcomes and increased mortality. The use of and outcomes associated with acute β-blocker therapy in patients with AMI complicated by sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and heart failure were investigated. Of 5,391 patients in the VALIANT Registry, sustained VT/VF occurred in 306 (5.7%), with an in-hospital mortality rate of 20.3%. Multivariable logistic regression identified sustained VT/VF as a major predictor of in-hospital death (relative risk 4.18, 95% confidence interval 2.91 to 5.93). Of those with sustained VT/VF, 55.2% were treated with intravenous or oral β blockade in the first 24 hours. After adjusting for baseline characteristics, propensity for acute β-blocker use, and the interaction between Killip classification and β-blocker therapy, β-blocker therapy within 24 hours was associated with decreased in-hospital mortality in patients with sustained VT/VF (relative risk 0.28, 95% confidence interval 0.10 to 0.75, p = 0.013) without evidence of worsening heart failure. Patients with sustained VT/VF were less likely to receive β blockers within 24 hours (p = 0.001). In conclusion, sustained VT/VF was common after AMI. In patients with sustained VT/VF, β-blocker therapy in the first 24 hours after AMI was associated with decreased early mortality without worsening heart failure. Unfortunately, β blockers were underused acutely in patients with sustained VT/VF.
      To read this article in full you will need to make a payment

      References

        • Solomon S.D.
        • Zelenkofske S.
        • McMurray J.J.
        • Finn P.V.
        • Velazquez E.
        • Ertl G.
        • Harsanyi A.
        • Rouleau J.L.
        • Maggioni A.
        • Kober L.
        • et al.
        Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
        N Engl J Med. 2005; 352: 2581-2588
        • Jánosi A.
        • Ghali J.K.
        • Herlitz J.
        • Czuriga I.
        • Klibaner M.
        • Wikstrand J.
        • Hjalmarson A.
        Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
        Am Heart J. 2003; 146: 721-728
        • Gislason G.H.
        • Abildstrom S.Z.
        • Rasmussen J.N.
        • Rasmussen S.
        • Buch P.
        • Gustafsson I.
        • Friberg J.
        • Gadsbøll N.
        • Køber L.
        • Stender S.
        • Madsen M.
        Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002.
        Scand Cardiovasc J. 2005; 39: 42-49
        • Perschbacher J.M.
        • Reeder G.S.
        • Jacobsen S.J.
        • Weston S.A.
        • Killian J.M.
        • Slobodora A.
        • Roger V.L.
        Evidence-based therapies for myocardial infarction: secular trends and determinants of practice in the community.
        Mayo Clin Proc. 2004; 79: 983-991
        • Velazquez E.J.
        • Francis G.S.
        • Armstrong P.W.
        • Aylward P.E.
        • Diaz R.
        • O'Connor C.M.
        • White H.D.
        • Henis M.
        • Rittenhouse L.M.
        • Kilaru R.
        • et al.
        An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT Registry.
        Eur Heart J. 2004; 25: 1911-1919
        • Al-Khatib S.M.
        • Stebbins A.L.
        • Califf R.M.
        • Lee K.L.
        • Granger C.B.
        • White H.D.
        • Armstrong P.W.
        • Topol E.J.
        • Ohman E.M.
        Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
        Am Heart J. 2003; 145: 515-521
        • Mehta R.H.
        • Harjai K.J.
        • Grines L.
        • Stone G.W.
        • Boura J.
        • Cox D.
        • O'Neill W.
        • Grines C.L.
        Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes.
        J Am Coll Cardiol. 2004; 43: 1765-1772
        • Killip III, T.
        • Kimball J.T.
        Treatment of myocardial infarction in a coronary care unit.
        Am J Cardiol. 1967; 20: 457-464
      1. Risk stratification and survival after myocardial infarction.
        N Engl J Med. 1983; 309: 331-336
        • Maggioni A.P.
        • Zuanetti G.
        • Franzosi M.G.
        • Rovelli F.
        • Santoro E.
        • Staszewsky L.
        • Tavassi L.
        • Tognoni G.
        Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era.
        Circulation. 1993; 87: 312-322
        • Henkel D.M.
        • Witt B.J.
        • Gersh B.J.
        • Jacobsen S.J.
        • Weston S.A.
        • Meverden R.A.
        • Roger V.L.
        Ventricular arrhythmias after acute myocardial infarction: a 20-year community study.
        Am Heart J. 2006; 151: 806-812
        • First International Study of Infarct Survival Collaborative Group
        Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1.
        Lancet. 1986; 2: 57-66
        • Rydén L.
        • Ariniego R.
        • Arnman K.
        • Herlitz J.
        • Hjalmarson A.
        • Holmberg S.
        • Reyes C.
        • Smedgård P.
        • Svedberg K.
        • Vedin A.
        • et al.
        A double-blind trial of metoprolol in acute myocardial infarction.
        N Engl J Med. 1983; 308: 614-618
        • Lichstein E.
        • Morganroth J.
        • Harrist R.
        • Hubble E.
        Effect of propranolol on ventricular arrhythmia.
        Circulation. 1983; 67: I5-I10
        • Braunwald E.
        • Antman E.M.
        • Beasley J.W.
        • Califf R.M.
        • Cheitlin M.D.
        • Hochman J.S.
        • Jones R.H.
        • Kereiakes D.
        • Kupersmith J.
        • Levin T.N.
        • et al.
        ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).
        J Am Coll Cardiol. 2002; 40: 1366-1374
        • Marciniak T.A.
        • Ellerbeck E.F.
        • Radford M.J.
        • Kresowik T.F.
        • Gold J.A.
        • Krumholz H.M.
        • Kiefe C.I.
        • Allman R.M.
        • Vogel R.A.
        • Jencks S.F.
        Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.
        JAMA. 1998; 279: 1351-1357
        • McMurray J.
        • Kober L.
        • Robertson M.
        • Dargie H.
        • Colucci W.
        • Lopez-Sendon J.
        • Remme W.
        • Sharpe D.N.
        • Ford I.
        Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
        J Am Coll Cardiol. 2005; 45: 525-530
        • Berger P.B.
        • Ruocco N.A.
        • Ryan T.J.
        • Frederick M.M.
        • Podrid P.J.
        Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis In Myocardial Infarction (TIMI) phase II trial.
        J Am Coll Cardiol. 1993; 22: 1773-1779
        • Roberts R.
        • Rogers W.J.
        • Mueller H.S.
        • Lambrew C.T.
        • Diver D.J.
        • Smith H.C.
        • Willerson J.T.
        • Knatterud G.L.
        • Forman S.
        • Passamani E.
        Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction.
        Circulation. 1991; 83: 422-437
        • Metoprolol In Acute Myocardial Infarction (MIAMI)
        A randomised placebo-controlled international trial.
        Eur Heart J. 1985; 6: 199-226
        • Hjalmarson A.
        • Elmfeldt D.
        • Herlitz J.
        • Holmberg S.
        • Málek I.
        • Nyberg G.
        • Rydén L.
        • Swedberg K.
        • Vedin A.
        • Waagstein F.
        • et al.
        Effect on mortality of metoprolol in acute myocardial infarction.
        Lancet. 1981; 2: 823-827
        • COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group
        Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1622-1632
        • Exner D.V.
        • Reiffel J.A.
        • Epstein A.E.
        • Ledingham R.
        • Reiter M.J.
        • Yao Q.
        • Duff H.J.
        • Follmann D.
        • Schron E.
        • Greene H.L.
        • et al.
        Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
        J Am Coll Cardiol. 1999; 34: 325-333
        • Brodine W.N.
        • Tung R.T.
        • Lee J.K.
        • Hockstad E.S.
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • Andrews M.
        • McNitt S.
        • Daubert J.P.
        Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
        Am J Cardiol. 2005; 96: 691-695
        • Jánosi A.
        • Ghali J.K.
        • Herlitz J.
        • Czuriga I.
        • Klibaner M.
        • Wikstrand J.
        • Hjalmarson A.
        • MERIT-HF Study Group
        Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
        Am Heart J. 2003; 146: 721-728
        • Nademanee K.
        • Taylor R.
        • Bailey W.E.
        • Reiders D.E.
        • Kosar E.M.
        Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy.
        Circulation. 2000; 102: 742-747
        • Koenig W.
        • Lowel H.
        • Lewis M.
        • Hörmann A.
        Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication.
        Eur Heart J. 1996; 17: 1199-1206
        • Soumerai S.B.
        • McLaughlin T.J.
        • Spiegelman D.
        • Hertzmark E.
        • Thibault G.
        • Goldmann L.
        Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.
        JAMA. 1997; 277: 115-121
        • Miller C.D.
        • Roe M.T.
        • Mulgund J.
        • Hoekstra J.W.
        • Santos R.
        • Pollack Jr., C.V.
        • Ohman E.M.
        • Gibler W.B.
        • Peterson E.D.
        Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction.
        Am J Med. 2007; 120: 685-692
        • Zipes D.P.
        • Camm A.J.
        • Borggrefe M.
        • Buxton A.E.
        • Chaitman B.
        • Fromer M.
        • Gregoratos G.
        • Klein G.
        • Moss A.J.
        • Myerburg R.J.
        • et al.
        ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.
        Circulation. 2006; 114: e385-e484